

N	EudraCT/ EU CTR Number	Trial Type	Trial Phase	Sponsor	Investigator	Title and Design	Trial Population	Age	R goal	R	R success	Recruiting	Duration
21	2024-514127-42-00	SIT	II	Neurocrine Biosciences, Inc.	PD Dr. med. Daniela Choukair	A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinicerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia (NBI-74788-CAH2011)	Infants and children with congenital adrenal hyperplasia	0 to < 2 years	2	1	50%	Yes	Since 10/2025
20	2022-501095-25	SIT	III	Amicus Therapeutics	Prof. Dr. med. Thomas Opladen	An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglusosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects with Infantile-onset Pompe Disease Aged 0 to < 18 Years (ATB200-08, ROSELLA)	Infants and children with Infantile-onset Pompe Disease	0 to < 18 years	2	1	50 %	Yes	Since 05/2025
19	2022-000956-12	SIT	I FIH	Biogen MA Inc.	Dr. med. Andreas Ziegler	A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study in Pediatric SMA Participants Previously Treated with Onasemnogene Apeparvovec (Zolgensma™) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115 (277HV101 study)	Part B: Children with SMA	0,5 to 12 years old	3	3	100 %	No	Since 12/2023
18	2020-003384-25	SIT	III	Ultragenyx Pharmaceutical Inc.	Prof. Dr. med. Thomas Opladen	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine	Adolescents and adult subjects with Late-Onset OTC Deficiency	>12 years	2	2	100 %	No	Since 01/2023

SIT: Sponsor-Initiated Trial (clinical trials with sponsors from pharmaceutical industry), IIT: Investigator-Initiated Trial, OS: Observation Study, R – Recruitment, recruited
Green lettering: Currently recruiting trials, blue lettering: All other trials

N	EudraCT/ EU CTR Number	Trial Type	Trial Phase	Sponsor	Investigator	Title and Design	Trial Population	Age	R goal	R	R success	Recruiting	Duration
						Transcarbamylase (OTC) in Patients with Late-Onset OTC Deficiency							
17	2021-000621-27	SIT	II	Travere Therapeutics, Inc.	Prof. Dr. med. Burkhard Tönshoff	A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK Study)	Children and adolescents with selected proteinuric glomerular diseases	≥1 year to <18 years	2	4	200 %	Yes	Since 12/2022
16	2021-000497-28	SIT	III	PTC Therapeutics	Prof. Dr. med. Thomas Opladen	A Phase 3 Open-Label Extension Study of PTC923 in Phenylketonuria ("PTC923-MD-004-PKU")	Male or female subjects of any age with Phenylketonuria	> 0 months	2	3	150 %	No	Since 11/2022
15	2021-002071-19	SIT	III	Bayer AG	Prof. Dr. med. Elke Wühl	A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria ("FIONA" Study)	Children and Adolescents with chronic kidney disease and proteinuria	6 months to <18 years	3	1	33 %	Yes	Since 06/2022
14	2020-004381-19	SIT	III	Neurocrine Biosciences Inc.	Prof. Dr. med. Markus Bettendorf	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment	Children and adolescents with classic congenital adrenal hyperplasia	6 – 17 years	15	1	7 %	No	Since 08/2022
13	2021-000474-29	SIT	III	PTC Therapeutics	Prof. Dr. med. Thomas Opladen	A Phase 3 Study of PTC923 in Subjects with Phenylketonuria ("PTC923-MD-003-PKU")	Male or female subjects of any age with Phenylketonuria	> 0 months	2	3	150 %	No	07/2022-07/2023

SIT: Sponsor-Initiated Trial (clinical trials with sponsors from pharmaceutical industry), IIT: Investigator-Initiated Trial, OS: Observation Study, R – Recruitment, recruited
Green lettering: Currently recruiting trials, blue lettering: All other trials

N	EudraCT/ EU CTR Number	Trial Type	Trial Phase	Sponsor	Investigator	Title and Design	Trial Population	Age	R goal	R	R success	Recruiting	Duration
12	2020-002798-92	SIT	III	Provention Bio	Dr. med. Kristine Chobanyan-Jürgens	A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents with Recent-Onset Type 1 Diabetes Mellitus ("PROTECT Extension Study")	Children and Adolescents with Recent-Onset Type 1 Diabetes Mellitus	> 9 years	4-5	5	100 %	No Roll-over from the PROTECT Study	Since 05/2022
11	2021-001083-16	SIT	II	Dicerna Pharmaceuticals Inc.	Prof. Dr. med. Burkhard Tönshoff	A Phase 2 Open-Label Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Nedosiran in Pediatric Patients from Birth to 11 Years of Age with Primary Hyperoxaluria and Relatively Intact Renal Function ("PHYOX8" Study)	Children with Primary Hyperoxaluria and Relatively Intact Renal Function	0-11 years	2	1	50 %	No	03/2022-11/2024
10	2020-000561-16	SIT	II	Novartis Pharma AG	Prof. Dr. med. Steffen Syrbe	EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)	Pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)	≥ 6 years	2	5	250 %	No	Since 10/2021
9	2018-003099-10	SIT	III	Dicerna Pharmaceuticals Inc.	Prof. Dr. med. Burkhard Tönshoff	An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria ("PHYOX3" Study)	Children and Adolescents with Primary Hyperoxaluria	≥ 6 years	1	1	100 %	No	12/2020-12/2025

SIT: Sponsor-Initiated Trial (clinical trials with sponsors from pharmaceutical industry), IIT: Investigator-Initiated Trial, OS: Observation Study, R – Recruitment, recruited
Green lettering: Currently recruiting trials, blue lettering: All other trials

N	EudraCT/ EU CTR Number	Trial Type	Trial Phase	Sponsor	Investigator	Title and Design	Trial Population	Age	R goal	R	R success	Recruiting	Duration
8	2018-003098-91	SIT	II	Dicerna Pharmaceuticals Inc.	Prof. Dr. med. Burkhard Tönshoff	A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria ("PHYOX2" Study)	Children and Adolescents with Primary Hyperoxaluria (Type 1 or Type 2)	≥ 6 years	1	1	100 %	No	06/2020-12/2020
7	2018-004926-26	SIT	III	Provention Bio, Inc.	Dr. med. Jürgen Grulich-Henn; Dr. med. Kristine Chobanyan-Jürgens	A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Diabetes (T1D) ("PROTECT" Study)	Children and Adolescents with Type 1 Diabetes	8 to 17 years	3	5	167 %	No	09/2020-05/2022
6	2019-002817-21	SIT	III	Janssen Cilag, GmbH	Prof. Dr. med. Matthias Gorenflo	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension ("SALTO" Study)	Children with Pulmonary Arterial Hypertension	2 to 18 years	3	0	0 %	No	Since 09/2020
5	N.A.	OS	N.A.	Albert-Ludwigs-University Freiburg (Medical Faculty)	Dr. med. Andreas Ziegler	SMArtCARE: Longitudinal data collection in patients with Spinal Muscular Atrophy (SMA)	Children with Spinal Muscular Atrophy	Birth to 18 years	open	80	ongoing	Yes	Since 04/2020

SIT: Sponsor-Initiated Trial (clinical trials with sponsors from pharmaceutical industry), IIT: Investigator-Initiated Trial, OS: Observation Study, R – Recruitment, recruited
Green lettering: Currently recruiting trials, blue lettering: All other trials

Track Record: Clinical trials in paedKIIPS

Heidelberg University Hospital, Center for Child and Adolescent Medicine and Internal Medicine IX - Dept. of Clinical Pharmacology and Pharmacoepidemiology

January 2026

Page 4 von 5

N	EudraCT/ EU CTR Number	Trial Type	Trial Phase	Sponsor	Investigator	Title and Design	Trial Population	Age	R goal	R	R success	Recruiting	Duration
4	N.A.	IIT (OS)	N.A.	Biogen GmbH (Sponsor Research Agreement)	Dr. med. Andreas Ziegler	Metabolic Profiling of Neuromuscular Diseases (MetabNMD) – subproject SMA	Children and adults with Spinal Muscular Atrophy	Birth to 99 years	300	Ca. 300	ongoing	Yes	Since 05/2020
3	2019- 001759- 38	IIT	I	Ruprecht-Karls University Heidelberg (Medical Faculty)	Prof. Dr. med. Matthias Gorenflo	Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects	Children with Congenital Heart Defects	2 to 6 years	20	15	75 %	No	12/2019- 07/2022
2	2020- 000561- 16	SIT	II	Kaleido Biosciences	Prof. Dr. med. Thomas Opladen	A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care	Adults with Urea Cycle Disorder	18 to 65 years	1	1	100 %	No	03/2020- 11/2021
1	2018- 003099- 10	SIT	III	Santhera Pharmaceuticals (Switzerland) Limited	Prof. Dr. med. Thomas Opladen	A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids (“SIDEROS” Study)	Children and adults with Duchenne Muscular Dystrophy	≥ 10 years	3	4	133 %	No	04/2019- 03/2021

SIT: Sponsor-Initiated Trial (clinical trials with sponsors from pharmaceutical industry), IIT: Investigator-Initiated Trial, OS: Observation Study, R – Recruitment, recruited
Green lettering: Currently recruiting trials, blue lettering: All other trials